00:55 , Feb 14, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Aneurysm Mouse studies suggest the CysLT1 inhibitor Singulair montelukast could help treat abdominal aortic aneurysm (AAA). In a mouse model of calcium chloride-induced AAA, Singulair decreased aortic dilation compared with no treatment. In a...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

Kyorin sales and marketing update

Kyorin launched montelukast in Japan to treat bronchial asthma and allergic rhinitis. Montelukast is a generic of Kipres, which Kyorin markets in Japan. The National Health Insurance (NHI) list price of generic montelukast is Y101.80...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Montelukast VersaFilm: Phase I data

Top-line data from an open-label, crossover Phase I trial in 8 healthy volunteers showed that the bioavailability of montelukast following a single dose of Montelukast VersaFilm was 52% greater compared to Singulair montelukast tablets. IntelGenx...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Montelukast VersaFilm: Phase I started

IntelGenx began an open-label Phase I trial to compare montelukast VersaFilm vs. Singulair montelukast in healthy volunteers. IntelGenx plans to repurpose the drug for degenerative diseases of the brain, such as mild cognitive impairment (MCI)...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Leukotriene C4 (LTC4); cysteinyl leukotriene receptor 2 (CYSLTR2; CysLT2); CysLT1

Other INDICATION: Poisoning Cell culture and mouse studies suggest inhibiting LTC4 or its receptors, CysLT1 and CYSLTR2 , could help treat chemotherapy-related toxicity. In a HeLa-derived cell line, the generic chemotherapies doxorubicin and 5-fluorouracil (5-FU)...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Montelukast sodium regulatory update

Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan   Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J.   Product: Montelukast sodium ( Kipres OD Tablets )   Business: Inflammation   Kyorin said Japan approved Kipres OD Tablets,...
08:00 , Nov 19, 2012 |  BioCentury  |  Strategy

Celgene's venture model

Although it has eschewed creating a corporate venture arm, Celgene Corp. has been an active investor in private biotechs for at least the last five years, tapping a network of scientists and VCs to identify...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Accolate zafirlukast inflammation data

Researchers from the University of Aberdeen reported data from 2 open-label pragmatic trials showing that leukotriene antagonists Singular and Accolate produced equivalent increases in MiniAQLQ scores vs. inhaled corticosteroid controller medication (ICS) as first-line therapy...
07:00 , Sep 8, 2008 |  BC Week In Review  |  Clinical News

Singulair montelukast inflammation data

An independent analysis of data from the double-blind LODO, TAPE and LOCCS trials was published in the Journal of Allergy and Clinical Immunology and showed that Singulair montelukast had a positive effect on emotional outlook...
07:00 , Sep 8, 2008 |  BC Week In Review  |  Clinical News

Singulair montelukast: Phase IV data

An independent analysis of data from the double-blind LODO, TAPE and LOCCS trials was published in the Journal of Allergy and Clinical Immunology and showed that Singulair montelukast had a positive effect on emotional outlook...